Rafferty Asset Management LLC Has $7.17 Million Holdings in TG Therapeutics, Inc. $TGTX

Key Points

• Rafferty Asset Management LLC reduced its stake in TG Therapeutics by 45.1%, owning approximately $7.17 million worth of the biopharmaceutical company after selling 149,551 shares.
• Despite the stake reduction, other institutions like CWM LLC and Golden State Wealth Management LLC increased their investments in TG Therapeutics, indicating continued interest in the company's potential.
• TG Therapeutics reported a quarterly earnings miss with earnings per share at $0.17, falling short of analysts' expectations, and revenue of $141.15 million, a 92.1% increase year-over-year.

Rafferty Asset Management LLC decreased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 45.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 181,861 shares of the biopharmaceutical company's stock after selling 149,551 shares during the period. Rafferty Asset Management LLC owned approximately 0.11% of TG Therapeutics worth $7,171,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. CWM LLC raised its stake in TG Therapeutics by 16.2% during the 1st quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock valued at $82,000 after purchasing an additional 290 shares during the last quarter. Golden State Wealth Management LLC raised its position in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of TG Therapeutics by 26.8% in the first quarter. Smartleaf Asset Management LLC now owns 2,416 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 511 shares during the period. Xponance Inc. grew its position in TG Therapeutics by 5.3% during the first quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company's stock worth $428,000 after buying an additional 543 shares in the last quarter. Finally, Choreo LLC grew its position in TG Therapeutics by 7.6% during the first quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company's stock worth $337,000 after buying an additional 602 shares in the last quarter. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $28.57 on Thursday. The firm has a market capitalization of $4.53 billion, a PE ratio of 77.22 and a beta of 1.95. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 12-month low of $21.11 and a 12-month high of $46.48. The firm has a 50-day moving average price of $33.69 and a 200 day moving average price of $35.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. During the same period in the previous year, the firm posted $0.04 earnings per share. The firm's revenue for the quarter was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the sale, the director directly owned 228,816 shares in the company, valued at $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.64% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a research report on Thursday, July 10th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $46.25.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.